[CAS NO. 2210228-45-6] SU0268

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [2210228-45-6]

Catalog

HY-139056

Brand

MCE

CAS

2210228-45-6

DESCRIPTION [2210228-45-6]

Overview

MDL	-
Molecular Weight	475.56
Molecular Formula	C26H25N3O4S
SMILES	O=C(C1=CC(C2=CC=C(S(=O)(NC3=CC4=C(C=C3)CCCN4C(C5CC5)=O)=O)C=C2)=CC=C1)N

For research use only. We do not sell to patients.

Summary

SU0268 is a potent and specific inhibitor of 8-Oxoguanine DNA glycosylase 1 (OGG1) . SU0268 regulates inflammatory responses during Pseudomonas aeruginosa infection ^[1] ^[2] ^[3] .

In Vitro

MTH1-depleted cells are less sensitive to the OGG1-specific inhibitor, SU0268 (5-10 μM), than their control shGFP counterparts ^[1] .
SU0268/IACS-4759 (5-20 μM, 48h) co-treated cells are more viable than the correspondingly-treated IACS-4759- or SU0268-treated cells ^[1] .
SU0268 does not bind DNA and thus interacts with OGG1 specifically rather than its substrate ^[2] .
SU0268 induces the release of type I IFN by the mitochondrial DNA-cGAS-STING-IRF3-IFN-β axis, which decreases bacterial loads and halts disease progression ^[3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay ^[1]

Cell Line:	A549 shGFP and shMTH1 (2000 cells per well).
Concentration:	0.1 μM, 0.5 μM, 1 μM, 2.5 μM, 5 μM, 7.5 μM, 10 μM.
Incubation Time:	24 or 48 h.
Result:	The shGFP cells were more susceptible to OGG1 inhibition via increasing SU0268 doses than the shMTH1 cells, especially at the 48 time-point.

In Vivo

SU0268 pretreatment (10 mg/kg, intranasally treated) increases survival rates compared with controls without SU0268 pretreatment in MH-S cells and C57BL/6N mice ^[3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Anesthetized C57BL/6N mice ^[3] .
Dosage:	10 mg/kg.
Administration:	Intranasally treated.
Result:	Significantly inhibits inflammatory responses and mitigates P. aeruginosa infection.

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL ( 210.28 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.1028 mL	10.5139 mL	21.0278 mL
5 mM	0.4206 mL	2.1028 mL	4.2056 mL
10 mM	0.2103 mL	1.0514 mL	2.1028 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (5.26 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (5.26 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (5.26 mM); Clear solution

* All of the co-solvents are available by MCE.